Synopsis
Synopsis
0
JDMF
0
VMF
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Dermofix
2. Dermoseptic
3. Ginedermofix
4. Mykosert
5. Sertaconazole
6. Sertaconazole Mononitrate
7. Zalain
1. 99592-39-9
2. Dermofix
3. Ertaczo
4. Zalain
5. Sertaconazole Mononitrate
6. Ginedermofix
7. Dermovit
8. Fi 7056
9. Sertaconazole (nitrate)
10. Fi-7045
11. 99592-39-9 (nitrate)
12. 1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole;nitric Acid
13. 1dv05410m5
14. Fi-7056
15. 1-[2-[(7-chloro-1-benzothien-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1h-imidazole Nitrate
16. 1h-imidazole, 1-(2-((7-chlorobenzo(b)thien-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-, Mononitrate
17. Dermoseptic
18. 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1h-imidazole; Nitric Acid
19. Fisderm
20. Extens
21. Onabet
22. Sr-05000001439
23. Unii-1dv05410m5
24. Sertaconazolenitrate
25. Ertaczo (tn)
26. Zalain (tn)
27. 1-(2-((7-chlorobenzo[b]thiophen-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-1h-imidazole Nitrate
28. 1h-imidazole, 1-(2-((7-chlorobenzo(b)thien-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-, Nitrate (1:1)
29. Ncgc00016966-01
30. Cas-99592-39-9
31. Dsstox_cid_25529
32. Dsstox_rid_80932
33. Dsstox_gsid_45529
34. Mls002154122
35. Schembl261807
36. Chembl1200725
37. Dtxsid2045529
38. Hy-b0736a
39. Hms1571a12
40. Hms2098a12
41. Hms2231n14
42. Hms3372h01
43. Hms3715a12
44. Sertaconazole Nitrate [mi]
45. Amy32537
46. Bcp09311
47. Tox21_110718
48. Ac-739
49. Fi7056
50. Mfcd00918063
51. S3161
52. Sertaconazole Nitrate [mart.]
53. Akos015888158
54. Akos015964610
55. Sertaconazole Nitrate [who-dd]
56. Ccg-221045
57. 1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; Nitric Acid
58. As-14332
59. Smr001233429
60. Sertaconazole Nitrate [orange Book]
61. Sertaconazole Nitrate [ep Monograph]
62. Ft-0674558
63. D08510
64. F20635
65. A846049
66. A851341
67. Sr-05000001439-3
68. Q27252298
69. 1-(2-((7-chlorobenzo(b)thien-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-1h-imidazole Mononitrate
70. 1-[2-[(7-chloranyl-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; Nitric Acid
71. 1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole,nitric Acid
1. Sertaconazole
2. Sertaconazol
3. Demofix
| Molecular Weight | 500.8 g/mol |
|---|---|
| Molecular Formula | C20H16Cl3N3O4S |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | 498.992710 g/mol |
| Monoisotopic Mass | 498.992710 g/mol |
| Topological Polar Surface Area | 121 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 513 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Ertaczo |
| PubMed Health | Sertaconazole (On the skin) |
| Drug Classes | Antifungal |
| Drug Label | ERTACZO (sertaconazole nitrate) Cream, 2%, contains the imidazole antifungal, sertaconazole nitrate. Sertaconazole nitrate contains one asymmetric carbon atom and exists as a racemic mixture of equal amounts of R and S enantiomers.Sertaconazole nit... |
| Active Ingredient | Sertaconazole nitrate |
| Dosage Form | Cream |
| Route | Topical |
| Strength | 2% |
| Market Status | Prescription |
| Company | Valeant Luxembourg |
| 2 of 2 | |
|---|---|
| Drug Name | Ertaczo |
| PubMed Health | Sertaconazole (On the skin) |
| Drug Classes | Antifungal |
| Drug Label | ERTACZO (sertaconazole nitrate) Cream, 2%, contains the imidazole antifungal, sertaconazole nitrate. Sertaconazole nitrate contains one asymmetric carbon atom and exists as a racemic mixture of equal amounts of R and S enantiomers.Sertaconazole nit... |
| Active Ingredient | Sertaconazole nitrate |
| Dosage Form | Cream |
| Route | Topical |
| Strength | 2% |
| Market Status | Prescription |
| Company | Valeant Luxembourg |
Antifungal Agents
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Topical
Solubilizers
Controlled & Modified Release
Thickeners and Stabilizers
Coating Systems & Additives
Film Formers & Plasticizers
Granulation
Digital Content
DATA COMPILATION #PharmaFlow
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
100
PharmaCompass offers a list of Sertaconazole Nitrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sertaconazole Nitrate manufacturer or Sertaconazole Nitrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sertaconazole Nitrate manufacturer or Sertaconazole Nitrate supplier.
PharmaCompass also assists you with knowing the Sertaconazole Nitrate API Price utilized in the formulation of products. Sertaconazole Nitrate API Price is not always fixed or binding as the Sertaconazole Nitrate Price is obtained through a variety of data sources. The Sertaconazole Nitrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Dermofix manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dermofix, including repackagers and relabelers. The FDA regulates Dermofix manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dermofix API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dermofix manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Dermofix supplier is an individual or a company that provides Dermofix active pharmaceutical ingredient (API) or Dermofix finished formulations upon request. The Dermofix suppliers may include Dermofix API manufacturers, exporters, distributors and traders.
click here to find a list of Dermofix suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Dermofix DMF (Drug Master File) is a document detailing the whole manufacturing process of Dermofix active pharmaceutical ingredient (API) in detail. Different forms of Dermofix DMFs exist exist since differing nations have different regulations, such as Dermofix USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dermofix DMF submitted to regulatory agencies in the US is known as a USDMF. Dermofix USDMF includes data on Dermofix's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dermofix USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dermofix suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Dermofix Drug Master File in Korea (Dermofix KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Dermofix. The MFDS reviews the Dermofix KDMF as part of the drug registration process and uses the information provided in the Dermofix KDMF to evaluate the safety and efficacy of the drug.
After submitting a Dermofix KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Dermofix API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Dermofix suppliers with KDMF on PharmaCompass.
A Dermofix CEP of the European Pharmacopoeia monograph is often referred to as a Dermofix Certificate of Suitability (COS). The purpose of a Dermofix CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Dermofix EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Dermofix to their clients by showing that a Dermofix CEP has been issued for it. The manufacturer submits a Dermofix CEP (COS) as part of the market authorization procedure, and it takes on the role of a Dermofix CEP holder for the record. Additionally, the data presented in the Dermofix CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Dermofix DMF.
A Dermofix CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Dermofix CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Dermofix suppliers with CEP (COS) on PharmaCompass.
A Dermofix written confirmation (Dermofix WC) is an official document issued by a regulatory agency to a Dermofix manufacturer, verifying that the manufacturing facility of a Dermofix active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Dermofix APIs or Dermofix finished pharmaceutical products to another nation, regulatory agencies frequently require a Dermofix WC (written confirmation) as part of the regulatory process.
click here to find a list of Dermofix suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dermofix as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Dermofix API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Dermofix as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Dermofix and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dermofix NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Dermofix suppliers with NDC on PharmaCompass.
Dermofix Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dermofix GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dermofix GMP manufacturer or Dermofix GMP API supplier for your needs.
A Dermofix CoA (Certificate of Analysis) is a formal document that attests to Dermofix's compliance with Dermofix specifications and serves as a tool for batch-level quality control.
Dermofix CoA mostly includes findings from lab analyses of a specific batch. For each Dermofix CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dermofix may be tested according to a variety of international standards, such as European Pharmacopoeia (Dermofix EP), Dermofix JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dermofix USP).
